Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component.

Trial Profile

Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Darolutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms ARADES
  • Sponsors Endo Pharmaceuticals; Orion
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 May 2016 Results of combined long-term safety and efficacy data from three studies including this study presented at the 111th Annual Meeting of the American Urological Association
    • 15 Apr 2014 Pooled interim analysis presented at the 29th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top